Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103555608B reveals high-efficiency biocatalytic route for chiral intermediate. Enables cost reduction and supply chain reliability for pharma.
Patent CN1376659A reveals a safe metal borohydride reduction system for high-purity chiral intermediates, offering significant cost and supply chain advantages.
Patent CN112899246B details novel KmAKR mutants for synthesizing chiral statin side chains with superior stability and stereoselectivity for API manufacturing.
Patent CN106754775B details ScCR1 mutants for Atorvastatin intermediate. Offers high stability and activity for cost-effective manufacturing.
Patent CN101962661B reveals high-efficiency carbonyl reductase for statin intermediates. Offers superior yield and cost reduction in pharmaceutical intermediate manufacturing.
Novel reduction method for dexpramipexole dihydrochloride. High purity, mild conditions, cost-effective API manufacturing solution.
Novel biocatalytic route for chloramphenicol synthesis offering high yield and reduced waste. Ideal for reliable antibiotic supplier partnerships.
Patent CN103408399B offers high-yield reduction. Reliable supplier for pharma intermediates with cost reduction potential.
Patent CN107531662A reveals a scalable Nebivolol synthesis route avoiding chromatography. This report analyzes cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN105017181A reveals a cost-effective route for Carfilzomib intermediates. Discover high-purity manufacturing solutions and supply chain advantages for proteasome inhibitors.
Patent CN103554016B reveals enzymatic synthesis for high-purity API intermediates. Achieve substantial cost reduction and supply chain reliability with scalable green chemistry solutions.
Patent CN10508767673A reveals high-yield biocatalytic route. Offers supply chain stability and cost reduction in chiral intermediate manufacturing for global partners.
Novel patent CN111377822B enables high-purity vilanterol production with reduced hazards and scalable industrial processes for global supply chains.
Patent CN117402920A details a novel ketoreductase mutant for asymmetric reduction. This report analyzes cost reduction in chiral drug manufacturing and supply chain reliability for global buyers.
Patent CN101665811A reveals high-ee biocatalytic route for ACEI intermediates, offering superior purity and scalable production capabilities.
Patent CN103589665A reveals a novel Rhodococcus qingshengii strain for high-purity (S)-CHBE production, offering significant cost reduction in API manufacturing.
Patent CN109749968A details Bacillus velezensis strain for efficient (R)-1,3-butanediol synthesis. Delivers high purity, mild conditions, and supply chain stability for pharmaceutical manufacturing.
Patent CN102465159A reveals a green microbial route for Eslicarbazepine. Discover cost-effective, high-purity manufacturing solutions for API intermediates.
Patent CN115260153B reveals high-yield synthesis for EGFR inhibitors. Offers cost reduction and supply reliability for pharmaceutical intermediates manufacturing globally.
Patent CN104263769A details yeast-based reduction for high-purity chiral intermediates. Offers scalable, cost-effective manufacturing solutions for global supply chains.